2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024
Open accessThe DOI matches its Crossref record; 240 of the 240 references it cites were found in a registry or an index; 152 of the 254 sources its claims cite were checked for support.
Abstract
The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
CoChat Summary
TL;DR
This ADA Standards of Care chapter provides updated recommendations for diagnosing and classifying diabetes, prediabetes, and related forms, including diagnostic thresholds, screening intervals, and classification categories. It emphasizes confirmatory testing, A1C limitations, risk-based screening, and special populations such as type 1 diabetes, gestational diabetes mellitus (GDM), cystic fibrosis–related diabetes (CFRD), posttransplantation diabetes mellitus (PTDM), pancreatic diabetes, and monogenic diabetes.
Key findings
- Diabetes diagnostic criteria: A1C ≥6.5% (≥48 mmol/mol), FPG ≥126 mg/dL (≥7.0 mmol/L), 2-h PG ≥200 mg/dL (≥11.1 mmol/L) during 75-g OGTT, or random plasma glucose ≥200 mg/dL (≥11.1 mmol/L) with classic hyperglycemic symptoms/crisis; absent unequivocal hyperglycemia, diagnosis requires two abnormal results. Prediabetes is defined by A1C 5.7–6.4% (39–47 mmol/mol), FPG 100–125 mg/dL (5.6–6.9 mmol/L; IFG), or 2-h PG 140–199 mg/dL (7.8–11.0 mmol/L; IGT).
- Classification includes type 1 diabetes (5–10% of diabetes), type 2 diabetes (90–95%), specific types due to other causes, and GDM. Misdiagnosis is common and can occur in ~40% of adults with new type 1 diabetes; type 1 diabetes staging shows ~44% 5-year risk of symptomatic disease at stage 1 and ~60% risk by 2 years and ~75% within 5 years at stage 2.
- Screening: begin at age 35 years for all adults; consider earlier in adults with overweight/obesity plus one or more risk factors; repeat at minimum 3-year intervals if normal. In children/adolescents, consider risk-based screening after puberty or age 10 years, whichever is earlier, with overweight/obesity plus risk factors.
- Special populations: GDM screening at 24–28 weeks; one-step IADPSG criteria increase GDM diagnosis (e.g., 11.5% vs 4.9% in a 2021 USPSTF review) without demonstrated improved health outcomes. CFRD occurs in about 20% of adolescents and 40–50% of adults with cystic fibrosis; annual OGTT screening begins by age 10, and A1C is not recommended for screening due to low sensitivity. PTDM diagnosis is best made once stable on immunosuppression, usually at least 45 days after transplantation, with OGTT preferred. Monogenic diabetes accounts for <5% of diabetes; 80–85% of neonatal diabetes cases have a monogenic cause, and 30–50% of KATP-related neonatal diabetes improves with high-dose oral sulfonylureas.
Methods
- Design: ADA Standards of Care clinical practice guideline/consensus recommendations, updated annually by the ADA Professional Practice Committee, an interprofessional expert committee.
- Data/sample: No primary study sample; the chapter synthesizes published evidence and expert consensus. It references an ADA evidence-grading system (A/B/C/E) detailed in the Introduction and Methodology.
- Main analysis: Narrative synthesis of diagnostic, classification, and screening evidence with graded recommendations; no meta-analysis or primary data collection is reported in this chapter.
Limitations
- Stated evidence gaps include insufficient evidence for continuous glucose monitoring (CGM) for screening/diagnosis of prediabetes or diabetes; unknown optimal screening interval; uncertain benefit of treating early abnormal glucose metabolism; lack of randomized controlled trials for treating versus not treating GDM diagnosed by IADPSG but not Carpenter-Coustan criteria; and limited data on how treating maternal hyperglycemia affects offspring metabolic outcomes.
- Stated classification/diagnostic limitations include common misdiagnosis (e.g., ~40% of adults with new type 1 diabetes), poorly understood type 2 diabetes genetics, inadequate genetic data in diverse populations, and A1C unreliability in conditions such as hemoglobin variants, pregnancy, glucose-6-phosphate dehydrogenase deficiency, HIV, hemodialysis, recent blood loss/transfusion, or erythropoietin therapy.
- Evident from the text: this is a consensus guideline rather than a primary systematic review or meta-analysis; recommendations are graded A/B/C/E, with some based on expert consensus (E), and many cited studies are observational/cohort rather than randomized trials.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 2.1 Flowchart for investigation of suspected type 1 diabetes in newly diagnosed adults, based on data from White European populations. 1 No single clinical feature con fi rms type 1 diabetes in isolation. 2 Glutamic acid decarboxylase (GAD) should be the primary antibody measured and, if negative, should be followed by islet tyrosine phosphatase 2 (IA-2) and/or zinc transporter 8 (ZnT8) where these tests are available. In individuals who have not been treated with insulin, antibodies against insulin may also be useful. In those diagnosed at < 35 years of age who have no clinical features of type 2 diabetes or monogenic diabetes, a negative result does not change the diagnosis of type 1 diabetes, since 5 -10% of people with type 1 diabetes do not have antibodies. 3 Monogenic diabetes is suggested by the presence of one or more of the following features: A1C < 58 mmol/mol ( < 7.5%) at diagnosis, one parent with diabetes, features of a speci fi c monogenic cause (e.g., renal cysts, partial lipodystrophy, maternally inherited deafness, and severe insulin resistance in the absence of obesity), and monogenic diabetes prediction model probability > 5% (diabetesgenes.org/exeter-diabetes-app/ModyCalculator). 4 A C-peptide test is only indicated in people receiving insulin treatment. A random sample (with concurrent glucose) within 5 h of eating can replace a formal C-peptide stimulation test in the context of classi fi cation. If the result is $ 600 pmol/L ( $ 1.8 ng/mL), the circumstances of testing do not matter. If the result is < 600 pmol/L ( < 1.8 ng/mL) and the concurrent glucose is < 4 mmol/L ( < 70 mg/dL) or the person may have been fasting, consider repeating the test. Results showing very low levels (e.g., < 80 pmol/L [ < 0.24 ng/mL]) do not need to be repeated. Where a person is insulin treated, C-peptide must be measured prior to insulin discontinuation to exclude severe insulin de fi ciency. Do not test C-peptide within 2 weeks of a hyperglycemic emergency. 5 Features of type 2 diabetes include increased BMI ( $ 25 kg/m 2 ), absence of weight loss, absence of ketoacidosis, and less marked hyperglycemia. Less discriminatory features include non-White ethnicity, family history, longer duration and milder severity of symptoms prior to presentation, features of the metabolic syndrome, and absence of a family history of autoimmunity. 6 If genetic testing does not con fi rm monogenic diabetes, the classi fi cation is unclear and a clinical decision should be made about treatment. 7 Type 2 diabetes should be strongly considered in older individuals. In some cases, investigation for pancreatic or other types of diabetes may be appropriate. 8 A person with possible type 1 diabetes who is not treated with insulin will require careful monitoring and education so that insulin can be rapidly initiated in the event of glycemic deterioration. 9 C-peptide values 200 -600 pmol/L (0.6 -1.8 ng/mL) are usually consistent with type 1 diabetes or maturity-onset diabetes of the young but may occur in insulin-treated type 2 diabetes, particularly in people with normal or low BMI or after long duration. Reprinted and adapted from Holt et al. (36).](https://figures.cochat.ai/paper-figures/7be96ed282694b1c85997763e16ae474/2-diagnosis-and-classification-of-diabetes-i-standards-of-care-in-diabetes2024-i-figure-1.png)

Verification
Claims the paper makes
99 Valid · 9 Not valid · 35 Not checked · 32 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“However , in 2003 the ADA adopted the new range of 100 -125 mg/dL (5.6 -6.9 mmol/L) to better de fi ne IFG so that the population risk of developing diabetes with IFG would be similar to that with IGT (11).”
What the sources say
- Disputedcites [11] Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, 2003, Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Diabetes Care sourceExperimental — accuracy not yet measured
In “The new criteria” (p. 8), the committee defines IFG as fasting plasma glucose of 110 to <126 mg/dL, not 100–125 mg/dL. The paper describes both IFG and IGT as risk factors for future diabetes, but it does not say the lower IFG threshold was adopted to make their population risks similar. (LLM, conf=0.91)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In most cases, such stressor steroidinduced hyperglycemia resolves by the time of discharge (142,143).”
What the sources say
- Partly supportedcites [142] Thomas, 2000, Early peri-operative hyperglycaemia and renal allograft rejection in patients without diabetes, BMC Nephrol sourceExperimental — accuracy not yet measured
The Results (Hyperglycaemia; page unavailable) show that mean glucose fell from immediately after surgery to the morning of day 2. The Discussion (page unavailable) describes steroid exposure and postoperative hyperglycaemia, but the paper does not report whether most patients’ hyperglycaemia resolved by discharge. (LLM, conf=0.82)
- Disputedcites [143] Chakkera, 2009, Hyperglycemia during the immediate period after kidney transplantation, Clin J Am Soc Nephrol sourceExperimental — accuracy not yet measured
The Abstract (Results) says hyperglycemia was sustained throughout hospitalization and that 66% of patients without pretransplantation diabetes required insulin at discharge. The Discussion says the authors did not know what proportion would ultimately recover, rather than finding that most cases resolved by discharge. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Because periodontal disease is associated with diabetes, the utility of screening in a dental setting and referral to primary care as a means to improve the diagnosis of prediabetes and diabetes has been explored (108 -110)”
What the sources say
- Not checked — no full text of the sourcecites [108] Lalla, 2013, Dental findings and identification of undiagnosed hyperglycemia, J Dent Res source
- Not checked — no full text of the sourcecites [109] Lalla, 2011, Identification of unrecognized diabetes and pre-diabetes in a dental setting, J Dent Res source
- Supportedcites [110] Herman, 2015, Screening for prediabetes and type 2 diabetes in dental offices, J Public Health Dent source
The Discussion (page unavailable) describes periodontal disease and its sequelae as risk factors for dysglycemia, supporting the general association claimed. The paper’s own Results (page unavailable) found no association between clinical evidence of periodontitis and dysglycemia in its study sample, so it should not be cited as demonstrating that association in this cohort. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In a community-based study of African American and non-Hispanic White adults without diabetes, baseline A1C was a stronger predictor of subsequent diabetes and cardiovascular events than fasting glucose (82).”
What the sources say
- Partly supportedcites [82] Selvin, 2010, Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults, N Engl J Med sourceExperimental — accuracy not yet measured
The Abstract Conclusions state that glycated hemoglobin was more strongly associated than fasting glucose with cardiovascular disease risk, but only similarly associated with diabetes risk. The study population was community-based and included Black and White adults without diabetes. Page numbers are not provided in our copy. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“The epidemiologic studies that formed the basis for recommending A1C to diagnose diabetes included only adult populations (112).”
What the sources say
- Could not verifycites [112] Cowie, 2010, Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988-2006, Diabetes Care sourceExperimental — accuracy not yet measured
The introductory discussion (page unavailable) says an international expert committee recommended A1C for diagnosis, but does not give the ages of participants in the epidemiologic studies behind that recommendation. The Research Design and Methods section (page unavailable) includes participants aged 12 and older in this paper’s own analysis; that does not establish the ages in the studies the committee relied on. Searches for adult-only evidence and pediatric populations did not resolve the claim. (LLM, conf=0.73)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
74 more claims · 46 with their cited sources checked
Create a free account to see all 175 claims and to verify the 3 references still open.
- Probably not a substantial claim. 29
- It may state two separate claims as one. 75
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HbA1c can be affected by some non-glycaemic factors, including anaemia due to iron deficiency or malaria, specific haemoglobin variants (eg, HbS and HbF), other haemoglobinopathies, polycythaemia due to living in high altitude, liver and kidney diseases, HIV, and specific drugs such as antiretroviral therapy for HIV.”
From Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants (2024) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many clinical guidelines recommend using a second confirmatory test for diabetes diagnosis and initiating treatment,6,21–23 although there is variation in this guidance.”
From Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants (2024) · cites this paper as [21]
Experimental — accuracy not yet measured
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045
Cho, N. H., Shaw, J. E., Karuranga, S., Huang, Y., da Rocha Fernandes, J. D., Ohlrogge, A. W., & Malanda, B. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.02.023 · Cited by 7,283
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1183 · Cited by 6,220
Diagnosis and classification of diabetes mellitus
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s081 · Cited by 5,974
Hyperglycemia and adverse pregnancy outcomes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707943 · Cited by 5,563
Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.
National Diabetes Data Group (1979) · Diabetes · doi:10.2337/diab.28.12.1039 · Cited by 4,909
International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes
The International Expert Committee (2009) · Diabetes Care · doi:10.2337/dc09-9033 · Cited by 3,185
Research works printed but not linked: 1
- International Diabetes Federation . IDF Diabetes Atlas, 10th edition. Brussels, Belgium, International Diabetes Federation, 2021. Accessed 26 September 2023. Available from https://www.diabetesatlas.org/atlas/tenth-edition/
Cited by
Items 901–1,000 of 2,029
Montenegro-González, G. C., Serrano, C. B., Ampudia‐Blasco, F. J., Navarro, H. G., Real, J. T., Peñarrocha‐Diago, M., & Martínez‐Hervás, S. (2025) · Diagnostics · doi:10.3390/diagnostics15070928 · Cited by 2
“The diagnosis of diabetes was considered according to the ADA criteria [27]: HbA1c ≥ 6.5%, fasting plasma glucose ≥ 126 mg/dL, 2 h plasma glucose ≥ 200 mg/dL or random glucose ≥ 200 mg/dL accompanied by classic hyper-glycemic symptoms or hyperglycemic crises.”
InfluentialPsychometric Properties and Dimensionality of the Greek Version of the Hypoglycemic Confidence Scale
Benioudakis, E. S., Kalaitzaki, A. E., Karlafti, E., Kapageridou, E., Ahanov, O., Kontoninas, Z., Savopoulos, C. G., & Didangelos, T. (2025) · Journal of Nursing Measurement · doi:10.1891/jnm-2024-0108 · Cited by 1
Gestational Diabetes: From Mechanism to Therapy – A Short Review
Cursaru, R., Bratu, A., Radulian, G., Pavelescu, M. L., Rusu, E., Cirstoiu, F. C., & Cursaru, A. (2024) · Romanian Journal of Military Medicine · doi:10.55453/rjmm.2024.127.6.10 · Cited by 4
Tratamiento actual de la enfermedad renal crónica
Salvador-González, B., Guerrero, S. C., Romano, J., Lumillo‐Gutiérrez, I., & Gonzalo, E. L. (2025) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/j.fmc.2024.08.004 · Cited by 1
Autoimmune hyperglycemia: beyond type 1 diabetes
Rutigliano, I., Gallo, F., Fini, G., Mansueto, M. L., Trischitta, V., & Paola, R. D. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02506-2 · Cited by 1
“Diabetes mellitus is a complex metabolic disorder, characterized by chronic hyperglycemia due to defects in insulin secretion, insulin action, or both [1].”
Is Now the Time to Review the Diabetes Diagnostic Criteria?
Berković, M. C., Strollo, F., & Ceriello, A. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70046 · Cited by 1
“…in diabetes based on blood glucose levels from fasting ( > 7 mmol/L), after a glucose challenge ( ≥ 11.1 mmol/L), and through haemoglobin A1c of ≥ 6.5% ( ≥ 48 mmol/mol), or for individuals exhibiting classic symptoms of hyperglycemia, random plasma glucose of ≥ 11.1 mmol/L at any time [3].”
InfluentialFarooqi, H., Choudhry, N., Saddique, M. N., et al. (2025) · BMC Medical Genomics · doi:10.1186/s12920-025-02152-1 · Cited by 1
“The diagnosis of T2DM was confirmed based on the American Diabetes Association (ADA) criteria [8], which include fasting plasma glucose ≥ 126 mg/dL, 2-hour plasma glucose ≥ 200 mg/dL during an oral glucose tolerance test, or HbA1c ≥ 6.5%.”
InfluentialAssessing prediabetes and cardiometabolic risk in Danish youth with obesity
Gaul, A. K., Holm, L. A., Hansen, T. F., Holm, J., & Fonvig, C. E. (2025) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2025-0095 · Cited by 1
Cheang, I., Zhu, X., Lu, X., Li, Y., Ni, G., Yang, Y., Zhang, Y., Ren, Q. W., Wu, M., Gao, R., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.040876 · Cited by 2
OKYAY, E. K., Güney, E., & Çoban, M. (2025) · Zeitschrift für Geburtshilfe und Neonatologie · doi:10.1055/a-2586-3747 · Cited by 2
Intrahospital Prevalence of Diabetes and Prediabetes in Medical Departments in Upper Austria
Heinzl, M. W., Resl, M., Kellermair, J., Steinwender, C., Mayr, B. M., Obereder, J., Fellner-Färber, R., Klammer, C., Hartl, S., Brandner, J., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14113668 · Cited by 2
“The prevalence of prediabetes is even more uncertain, as it depends on the diagnostic criteria used—impaired fasting glucose (IFG), impaired glucose tolerance (IGT), or HbA1c values between 5.7% and 6.4% [8,9].”
InfluentialChen, H., Chen, Z. B., Cao, D., Jia, J., Chen, X., Yang, J., & Zhang, L. (2025) · BMC Sports Science Medicine and Rehabilitation · doi:10.1186/s13102-025-01187-2 · Cited by 3
A Study on the Correlation Between Calcific Aortic Valve Disease and Carotid Artery Elasticity
Zhang, Y., Wang, H., Zhong, Y., Wang, W., Zhang, Z., & He, Q. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm26821 · Cited by 1
Suarez, A. S. C., Hama, T., Johnson, M. P., Abraham, H. M., Olson, T. P., & Brewer, L. C. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.039010 · Cited by 2
“35,36 Furthermore, continued research is essential to enhance CR protocols and optimize metabolic outcomes in this patient population.”
Dias, R. J., Neves, J. S., & Poínhos, R. (2025) · Nutrients · doi:10.3390/nu17121951 · Cited by 2
Kajonwiboolpol, S., Patoomwan, A., & Punyoo, J. (2025) · Pacific Rim International Journal of Nursing Research · doi:10.60099/prijnr.2025.272686 · Cited by 2
Orces, C. H. (2025) · Journal of Bone Metabolism · doi:10.11005/jbm.24.831 · Cited by 1
“[19] Hypertension was defined as a systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 80 mmHg based on the mean of three consecutive blood pressure readings or reporting the use of prescribed medications for hypertension [20] Participants were considered to have a prevalent…”
Früherkennung des Typ-1-Diabetes im Kindesalter: Das Fr1da-plex-Netzwerk in Deutschland
Berge, T. V. D., Achenbach, P., Gemulla, G., Hummel, S., Loff, A., Kordonouri, O., & Fr1da-plex-Studiengruppe, D. (2025) · Monatsschrift Kinderheilkunde · doi:10.1007/s00112-025-02202-z · Cited by 1
Cagigas, M. L., Masedunskas, A., Lin, Y., Emery‐Corbin, S. J., Yousef, J. M., Dagley, L. F., Olechnowicz, S. W. Z., Bowden, R. J., Hayward, R., Low, G. K. K., et al. (2025) · Aging Cell · doi:10.1111/acel.70123 · Cited by 2
“Adults with overweight/obesity (BMI ≥ 25 kg/m 2 ; age 25–70 years) and prediabetes, defined by American Diabetes Association criteria (Committee et al. 2024) (fasting plasma glucose levels of 5.6–6.9 mmol/L and/or 2-h glucose levels of 7.8–11.0 mmol/L after a 75-g glucose challenge), were recruited…”
InfluentialRannan-Eliya, R. P., Wijemunige, N., Herath, H. M. M., Perera, P. N., Dissanayake, V. H. W., Perera, B., Dalpatadu, S., Samarage, S., & Gamage, A. U. (2025) · Health Systems & Reform · doi:10.1080/23288604.2025.2516904 · Cited by 2
“…guidelines, we defined undiagnosed diabetes as meeting either or both of these criteria: (i) fasting plasma glucose (FPG) ≥126 mg/dL (7.0 mmol/L) or (ii) 2-hour plasma glucose during OGTT (2-h PG) of ≥200 mg/dL (11.1 mmol/L), 22 considering only participants without a prior diabetes diagnosis.”
InfluentialSingh, A., Samajdar, S. S., Singh, A. K., TIWASKAR, M. H., & Joshi, S. (2025) · Journal of the Association of Physicians of India · doi:10.59556/japi.73.1010 · Cited by 3
Formichi, C., Caprio, S., Auddino, S., Rizza, F., Paolini, B., Nigi, L., & Dotta, F. (2025) · Human Nutrition & Metabolism · doi:10.1016/j.hnm.2025.200330 · Cited by 1
Berthoumieux, A., Naqvi, J. B., Zion, S. R., Napoleone, J. M., McGuill, A., Cerrada, C. J., Lee, H. J., Dunn, T. C., Kerr, D. E., Jasik, C. B., et al. (2026) · Journal of Medical Internet Research · doi:10.2196/78321 · Cited by 2
“Persistent hyperglycemia, as estimated by hemoglobin A 1c (HbA 1c ) [1], increases the risk of severe diabetes complications, including but not limited to vision loss, renal failure, and cardiovascular disease [2].”
Sultan, W., & Spencer, J. (2025) · Cureus · doi:10.7759/cureus.87031 · Cited by 3
Gherbon, A., Frandeș, M., Toderescu, C. D., Dîrpeş, D., Timar, R. Z., Nicula, M., Dascau, C., Daniluc, R., & Timar, B. (2025) · Medicina · doi:10.3390/medicina61071190 · Cited by 1
“The diagnosis of GDM is made when any of the following plasma glucose values are met or exceeded: Fasting: 92 mg/dL (5.1 mmol/L), 1h: 180 mg/dL (10.0 mmol/L), or 2h: 153 mg/dL (8.5 mmol/L) [18].”
InfluentialWu, Y., Zhang, Y., Liu, X., Liu, J., He, Z., Wei, Y., Zeng, Q., & Guo, R. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1451942 · Cited by 1
Hegab, A. M., & Abou‐Taleb, A. (2025) · Pediatric Diabetes · doi:10.1155/pedi/1283259 · Cited by 2
“In our pediatric diabetes unit, diagnosis of diabetes mellitus in children and adolescents was done based on the American Diabetes Association clinical, blood glucose, and glycosylated hemoglobin criteria [29].”
Clausen, C. L., Bryrup, T., Hansen, C. L., Faurholt‐Jepsen, D., Meddis, A., Almdal, T., Snorgaard, O., Jørgensen, H. L., Helleberg, M., Smitt, M., et al. (2025) · Annals of Intensive Care · doi:10.1186/s13613-025-01512-5 · Cited by 1
“Diabetes status was grouped into three categories by HbA1c levels according to the American Diabetes Association [19]: Normoglycemia (HbA1c < 39 mmol/mol), Prediabetes (39 mmol/mol ≤ HbA1c ≤ 47 mmol/mol), and Diabetes consisting of either (1) a known diagnosis of diabetes or glucose-lowering…”
Zhao, L., Zhao, C., Fu, Y., et al. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1641496 · Cited by 1
Thành, N. Đ., Toán, V. N., Toan, D. N., & Trang, V. M. (2025) · Archiv der Pharmazie · doi:10.1002/ardp.70039 · Cited by 1
Zhu, Y. Y., Cheng, Q., Liao, W., Wang, H., & Wang, R. (2025) · Medicine · doi:10.1097/md.0000000000043311 · Cited by 3
“[14] Singleton pregnancy with an ante-natal file established after 12 weeks of gestation at our hospital, and follow-up for pregnancy outcomes, with good cooperation.”
CLCF1 contributes to high-glucose-induced EndMT by modulating JAK2/STAT3 signaling
Deng, R., He, K., You, Q., Zhang, W., Ma, X., Zhou, X., Kong, Y., & Wang, J. (2025) · European journal of medical research · doi:10.1186/s40001-025-02932-6 · Cited by 1
Chen, S. (2025) · American Journal of Translational Research · doi:10.62347/atjv9203 · Cited by 1
Lin, A., Peng, Y., Shao, J., et al. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s525296 · Cited by 1
Andersen, A. K., Lyng, K. D., Færch, K., Vistisen, D., von Scholten, B. J., Rathleff, M. S., Thomsen, J. L., & Jensen, M. H. (2025) · Diabetologia · doi:10.1007/s00125-025-06505-4 · Cited by 2
“[3 , 6, 7].”
Gu, J., Qiu, S., & Sun, Z. (2025) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s530939 · Cited by 1
Salsabila, T., Fa’rifah, R. Y., & Pramesti, D. (2025) · International Conference on Electronics Representation and Algorithm (ICERA) · doi:10.1109/icera66156.2025.11087261 · Cited by 1
“Similarly, [17] underscored the role of HbA1c as an indicator for long-term glycemic control, which is critical in evaluating whether diabetes treatment is successful.”
Tripathi, P., Tiwari, D., KADAM, N. S., VYAWAHARE, A. R., Sharma, B., Kathrikolly, T., GANLA, M. H., & Saboo, B. (2025) · Journal of Diabetes Research · doi:10.1155/jdr/6172692 · Cited by 3
Hernandez-Moreno, C. J., Falkner, B. E., Keith, S. W., Gidding, S. S., & Thaker, V. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf435 · Cited by 2
Yang, C., Chen, Q., Li, W., Gao, C., Han, Y. Y., & Zhu, J. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1627337 · Cited by 1
Zhou, F., Dong, Y., Yu, L., Chen, S., & Tan, L. (2025) · Medicine · doi:10.1097/md.0000000000043987 · Cited by 1
“Diabetes was defined as meeting any of the following criteria [20,22] : self-reported diagnosis, current use of insulin or oral hypoglycemic agents, hemoglobin A1c ≥ 6.5%, fasting blood glucose ≥ 7.0 mmol/L, or 2-hour postprandial glucose ≥ 11.1 mmol/L. Hypertension was defined by meeting at least…”
InfluentialHaynes, A., Smith, G. J., Tully, A. S., Mellor, B.-R., Penno, M. A. S., Craig, M. E., Wentworth, J. M., Huynh, T., Colman, P. G., Soldatos, G., et al. (2025) · Diabetes Care · doi:10.2337/dc25-0821 · Cited by 1
Haruyama, R., Rahman, M. S., Rahman, M. M., Khim, S. A., Moadsiri, A., Chham, S., Chhim, S., Kol, H., & Phy, M. (2025) · Journal of Global Health · doi:10.7189/jogh.15.04251 · Cited by 2
Gwan, A., Ortiz, I., Tessier, K., Mahr, R. M., Looby, A. A., Molleti, S., Makori, J., Akingbola, O., Nashif, S. K., Karbeah, J., et al. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005197 · Cited by 1
Fan, K., Yen, I., Lin, C., Yang, C., Kuo, C., Chen, S.-C., Lyu, Y., Juan, H.-C., Lin, M., Wang, S., et al. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01890-7 · Cited by 2
“Diabetes was diagnosed according to the American Diabetes Association criteria when FPG was ≥ 126 mg/dL (7 mmol/L), 2hPG in the 75-g OGTT was ≥ 200 mg/dL (11.1 mmol/L), HbA1c was ≥ 6.5%, or if the subject was taking diabetes medication [18].”
InfluentialTaban, G., Başaran, N. Ç., & Ayaz, A. (2025) · PeerJ · doi:10.7717/peerj.19957 · Cited by 2
“For the control group, healthy participants with HbA1c 5.7% and FBG 100 mg/dL were accepted ( American Diabetes Association Professional Practice Committee, 2024 ).”
InfluentialZhang, Y., Hu, X., Xu, W., Chen, Y., Guo, X., Liu, S.-H., & Gao, L. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i9.104290 · Cited by 1
Risk Factors for Hypertension in Polycystic Ovary Syndrome: Evidence from a Retrospective Study
Robeva, R. N., Elenkova, A. P., Кirilov, G., Kalinov, K., & Zacharieva, S. (2025) · Life · doi:10.3390/life15091416 · Cited by 1
“…presence of type 2 diabetes mellitus (DMT2), impaired fasting glucose (IFG), and impaired glucose tolerance (IGT) were estimated according to global recommendations [25,26] based on the previous medical history of the patients or the actual glucose investigations at the first visit in the clinic.”
Kehar, S., Bhatt, S. P., Pandey, R. M., Ansari, I. A., Palavalli, R. R., Gupta, V. K., & Misra, A. (2025) · European Journal of Clinical Nutrition · doi:10.1038/s41430-025-01659-1 · Cited by 1
Li, X., Wang, Y., Zhang, T., Rang, W., & Liu, Y. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01717-2 · Cited by 1
“In addition to genetics and lifestyle, environmental factors have also emerged as significant contributors to diabetes risk [ 7 , 8 ].”
Kalaydzhiev, P., Velikova, T. V., Voynova, G., Ilieva, R., Spasova, N., Yakov, S., Kinova, E., Vasilev, G., Wells, R. N., & Goudev, A. (2025) · Pharmacia · doi:10.3897/pharmacia.72.e166690 · Cited by 1
José, M. R.-R., Rosa, M. D. Á., Carlos, N. F.-M., Cordero‐Rivera, C. D., Jesús‐González, L. A. D., Selvin, N. P.-R., Juan, F. O.-R., Gustavo, M.-M., Noel, J. S.-J., Bernal-Dolores, V., et al. (2025) · World Journal of Emergency Medicine · doi:10.5847/wjem.j.1920-8642.2025.105 · Cited by 1
Preperimetric glaucoma: conversion to primary open-angle glaucoma in a 10-year follow-up
Lee, J., Kim, Y. K., Park, K. H., et al. (2025) · British Journal of Ophthalmology · doi:10.1136/bjo-2024-327048 · Cited by 1
Joshi, M., Pickard, A. S., Kim, K., Sharp, L. K., Gerber, B. S., & Touchette, D. R. (2025) · Quality of Life Research · doi:10.1007/s11136-025-04070-2 · Cited by 1
Jiang, C., Yang, Q., Hou, X., et al. (2025) · BMC Medical Imaging · doi:10.1186/s12880-025-01919-3 · Cited by 1
“Non-diabetic/Diabetic: Diabetes mellitus was defined according to the American Diabetes Association (ADA) criteria, which includes a previous diagnosis, active use of glucose-lowering therapy, fasting plasma glucose ≥126 mg/dL, or HbA1c ≥ 6.5% [34].”
InfluentialMen, X., Yue, P., Hao, W., Zhang, L., Chen, E., & Liu, J. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1646690 · Cited by 1
Can health literacy reduce the risk of chronic complications in diabetic patients?
Erişmiş, B., Şimşekoğlu, N., Gurdal, M. F. D., Erken, N., Pasin, Ö., & Şahiner, E. S. (2025) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2025.10.002 · Cited by 1
Ryoo, S. W., Lin, W. Z., Magliocco, A., Ruthirakuhan, M. T., Wong, Y. Y., Perfetto, S. E., Huang, C., Anita, N. Z., Arnott, S. R., Lang, A. E., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70718 · Cited by 1
“24 Secondaryanalysesexaminedpatients by strata approximating clinical glycemic status 25 ; normoglycemia, prediabetes, and T2DM were ascertained via self-reported physician diagnosis of diabetes, use of antidiabetic medication, and HbA1c measured during the baseline visit.”
Zhao, W., Niu, X., Zhou, X., Shi, R., & Zhou, X. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33885-4.00007-x · Cited by 1
Alam, G. M. I., Biswas, T., Tanim, S. A., & Mridha, M. F. (2025) · Healthcare Analytics · doi:10.1016/j.health.2025.100422 · Cited by 10
Yi, M., Lin, W., Liu, S., Zhang, Y., Song, J., Yin, Y., & Ding, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1692185 · Cited by 1
Bachmann, A., Estermann, J., Sourouni, M., Karn, T., Bitterlich, N., Weidlinger, S., & Stute, P. (2025) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-025-08219-9 · Cited by 1
“Elevated fasting glucose and a history of gestational diabetes were classified as risk factors for type 2 diabetes [17].”
Waheed, H. J., & Numan, N. A. M. (2025) · PeerJ · doi:10.7717/peerj.20086 · Cited by 4
Malandrino, N., Davis, F., Glaros, S. B., KACKER, I. N., CANTOR, S. L., Macheret, N. A., THOTA, G. P., Mabundo, L. S., Sampson, M. L., Remaley, A. T., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02951-x · Cited by 2
“1) [27].”
Saboo, B., Kalra, P., Majumdar, S., Phatak, S., Deka, N., Kadam, Y., Kotru, S., Shivane, V. K., Nanditha, A., Tyagi, P., et al. (2025) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_29_25 · Cited by 3
Lin, M., Li, C., Wu, H., Lee, C., Chen, H.-P., Ou, H., & Kuo, H. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14217599 · Cited by 1
“Classification was performed according to the diagnostic criteria of the American Diabetes Association (ADA) using the results of a OGTT [21].”
Jiang, Y., Zhao, M., Li, M., Zhu, H., Kong, X., Liu, Q., Liu, Y., Gao, P., Deng, G., Zhao, H., et al. (2025) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2686-7562 · Cited by 1
“This personalized nutritional approach rep - resents a significant advancement beyond current standardized di - etary guidelines [25] and aligns with the growing recognition of precision nutrition in diabetes management [26].”
Mohamed, F., Gunter, S., Yirdaw, B. E., Raal, F. J., Millen, A. M. E., & Kalla, I. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-02056-2 · Cited by 3
“Additionally, DM was confirmed by an FPG level of ≥ 126 mg/dL (≥ 7.0 mmol/L) or the presence of classic symptoms of hyperglycemia or hyperglycemic crisis, evidenced by a random plasma glucose level of ≥ 200 mg/dL (≥ 11.1 mmol/L) [37].”
InfluentialAlbitres‐Flores, L., Huayanay-Espinoza, C. A., Safary, E., Vetter, B., Cahuana-Hurtado, L., Lazo‐Porras, M., & Bernabé‐Ortiz, A. (2025) · BMC Health Services Research · doi:10.1186/s12913-025-13554-3 · Cited by 3
“…Peruvian guideline and on the American Diabetes Association criteria (fasting plasma glucose ≥ 126 mg/dL (7.0 mmol/L); HbA1c ≥ 6.5% (48 mmol/mol)) [24, 25]; hypercholesterolemia was defined as total cholesterol ≥ 200 mg/ dL (5.18 mmol/L) [26, 27]; and kidney disease as creatinine > 1.1 mg/dL…”
InfluentialKumar, A. S., Oldenburg, B. F., & Thirunavukkarasu, S. (2025) · Journal of Diabetology · doi:10.4103/jod.jod_25_25 · Cited by 1
Fatima, N., Kiran, Z., Khan, M. T., Baloch, A. A., Shaikh, K. U. S., & Hasan, S. M. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04506-4 · Cited by 1
“The World Health Organization (WHO) and American Diabetes Association (ADA) criteria are recommended for the diagnosis of impaired glucose tolerance (IGT) and diabetes by the International Consensus Guidelines designed in 2003 and revised in 2014 for PTDM [11, 12].”
Huang, H.-L., Shi, S. Y., & Li, D. (2025) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2025.101438 · Cited by 2
Sun, Y., Niu, X., Wang, Y., Zhang, Q., Liu, Y., He, J., Xu, L., Wang, R., & Guo, J. (2025) · Nutrients · doi:10.3390/nu17213438 · Cited by 3
“…impaired fasting blood glucose is defined as a fasting blood glucose level of 5.6–6.9 mmol/L; impaired glucose tolerance is defined as a 2 h postprandial glucose (2 h PG) level of 7.8–11.0 mmol/L; or prediabetes can also be defined as a glycosylated hemoglobin level of 5.7–6.4% [27,28].”
InfluentialLi, K., Li, L., Pan, L., Huang, A., Zhang, H., Xu, Y., Nong, Z., & Huang, R. (2025) · International Journal of General Medicine · doi:10.2147/ijgm.s550519 · Cited by 1
Hemoglobin A1c Screening Practices and Characteristics in Youth with Congenital Heart Disease
Wheeler, J. A., Cheng, P. S., Alvarado, C., Mamilly, L., Walsh, A. T., Hor, K. N., & Tran, A. H. (2025) · Pediatric Cardiology · doi:10.1007/s00246-025-04092-0 · Cited by 1
Chen, Y., Zhao, J., Sun, Y., Yang, Z., Yang, C., & Zhu, D. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1697718 · Cited by 1
García-Gorrita, C., Onofre, N. S., Merino-Torres, J. F., & Soriano, J. M. (2025) · Nutrients · doi:10.3390/nu17223559 · Cited by 4
“Accordingly, ADA guidelines recommend ≥ 150 g of carbohydrates/day during the 3 days prior to an OGTT to avoid false positives due to under-adaptation [37].”
Chen, L., Wang, L., Fu, A., Yang, J., Lan, Y., Wang, Z., Wang, D., & Cheng, S. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70297 · Cited by 2
Shui, L., Liu, Q., Liu, X., Bai, H., Wu, Y., Sheng, Y., He, G., & Fan, P. (2025) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-025-08436-9 · Cited by 1
Huwaimel, B., Alqarni, S., Abouzied, A. S., Alghubayshi, A., Alotaibi, T., Elshafei, A., Yassien, M., Nasr, M. S. M., & Khidr, E. G. (2025) · Medicina · doi:10.3390/medicina61122089 · Cited by 1
“The diagnosis of T2D was based on the American Diabetes Association 2024 criteria [19].”
Fang, Y., Zhao, J., Xu, H., Shen, J., Wei, X., Huang, Q., Hu, W., & Lv, L. (2025) · European journal of medical research · doi:10.1186/s40001-025-03517-z · Cited by 1
Qiao, L., Miao, J., Du, W., Liu, Y., Chen, Y., Xu, K., Wang, C., & Chen, H. (2025) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2025.1688715 · Cited by 1
Birgün, A., Çelik, M. C., Kalçık, M., Yetim, M., Bekar, L., & Karavelioğlu, Y. (2025) · Exploration of Cardiology · doi:10.37349/ec.2025.101283 · Cited by 1
Association of sarcopenia with vascular complications in patients with type 2 diabetes mellitus
Thorat, S. T., & Patil, V. C. (2025) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-025-01601-y · Cited by 1
Navarrete, R. E. T., Freitas, J. C., Fonseca, I. M., Cunha, A., de Sá, J. R., & Martins, L. S. (2025) · Diabetology · doi:10.3390/diabetology6120158 · Cited by 1
“T2DM and PTDM were diagnosed according to American Diabetes Association (ADA) criteria [21]: ≥ 1 of the following—FPG ≥ 126 mg/dL; 2 h plasma glucose ≥ 200 mg/dL during a 75 g oral glucose tolerance test; HbA1c ≥ 6.5%; or random plasma glucose ≥ 200 mg/dL with classic hyperglycemic symptoms.”
InfluentialRuseva, A., Michalak, W., Fabricatore, A. N., Hartaigh, B. Ó., Zhao, Z., Wang, J., & Umashanker, D. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2591464 · Cited by 3
“%) based on the result closest to the time point of interest 23 .”
Altered static and dynamic intrinsic brain activity patterns in type 2 diabetic patients
Liang, Y., Liu, W. V., Li, M., Feng, Q., Wei, S., Yang, W., Guan, Z., Li, J., Wei, W., Li, M., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-30847-z · Cited by 1
Peng, W., Yang, X., Deng, Y., Wu, J., Mo, P., Liu, Y., Ji, L., Liu, P., Liao, J., Zhang, A., et al. (2025) · Current Neurovascular Research · doi:10.2174/0115672026421915251115074018 · Cited by 1
Roth, L., Bretschneider, M. P., & Schwarz, P. E. H. (2025) · Frontiers in Digital Health · doi:10.3389/fdgth.2025.1644612 · Cited by 2
Yang, C., Wang, Y., Weng, X., Wang, R., Xu, J., & Luo, D. (2025) · Pediatric Research · doi:10.1038/s41390-025-04644-3 · Cited by 1
Cui, Y., Li, L., Li, Y., & Yu, P. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s572295 · Cited by 1
da Cruz, S. B. A., Costa, R. C., Flores, F. D. S., Borges, M. H. R., Matsushita, D. H., Bertolini, M., da Cruz, N. C., Souza, J. G. S., Ervolino, E., Barão, V. A. R., et al. (2025) · ACS Omega · doi:10.1021/acsomega.5c08289 · Cited by 1
Liu, Z., Li, M., Chen, Y., Wang, C., Chen, J., Long, H., Liu, R., Chiou, J. A., & Chen, C. (2025) · Nutrients · doi:10.3390/nu18010112 · Cited by 2
Zhao, C. F., Yang, W. H., Zhao, Z., et al. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005366 · Cited by 1
Frigerio, F., Vitozzi, A., Piciocchi, C., Ricci, F., Marinis, M. G. D., Galfano, V., Lubrano, C., Mariani, S., Gangitano, E., Minnetti, M., et al. (2026) · International Journal of Obesity · doi:10.1038/s41366-025-01993-1 · Cited by 2
Abdulsalam, T. A., & Ali, S. (2026) · Cureus · doi:10.7759/cureus.100769 · Cited by 1
Alrossies, A. S., Alsubaie, N., Shah, Z. A., Ilyas, M., Habib, I., Saddique, G., & Shah, S. M. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1735170 · Cited by 3
Yacouba, A., Sidibe, R., Dalla, A.-S. C. S., Issa, A., Saley, S. M., Tapha, O., Bassirou, A. N., Doutchi, M., Brah, S., Abdoul-Wahab, I. M., et al. (2026) · Frontiers in Virology · doi:10.3389/fviro.2025.1717896 · Cited by 1
“Hyperglycemia thresholds were based on the 2024 American Diabetes Association (ADA) guidelines (24).”
Fattah, S. M. A., Abbassi, M., elshafy, S. A. A., Hegazy, M., & Farid, S. F. (2026) · European Journal of Clinical Nutrition · doi:10.1038/s41430-025-01693-z · Cited by 3
“Traditional dietary strategies, such as low-carbohydrate diets, portion control, and balanced nutrition, focus on optimizing glycemic control [1].”
Influential
Metadata
- Authors
- American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., Khunti, K., Lingvay, I., Matfin, G., McCoy, R. G., Perry, M. L., Pilla, S. J., Polsky, S., Prahalad, P., Pratley, R. E., Segal, A. R., Seley, J. J., Selvin, E., Stanton, R. C., & Gabbay, R. A.
- ORCID
- ElSayed, Nuha A.
- Aleppo, Grazia
- Bannuru, Raveendhara R.
- Bruemmer, Dennis
- Collins, Billy S.
- Ekhlaspour, Laya
- Gaglia, Jason L.
- Hilliard, Marisa E.
- Johnson, Eric L.
- Khunti, Kamlesh
- Lingvay, Ildiko
- McCoy, Rozalina G.
- Perry, Mary Lou
- Pilla, Scott J.
- Polsky, Sarit
- Prahalad, Priya
- Pratley, Richard E.
- Segal, Alissa R.
- Seley, Jane Jeffrie
- Selvin, Elizabeth
- Stanton, Robert C.
- Gabbay, Robert A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2023-12-11
- Volume
- 47
- Issue
- Supplement_1
- Pages
- S20-S42
- ISSN
- 0149-5992 (ISSN-L)
- PMC
- PMC10725812
- OpenAlex
- W4389560718
- Cited by
- 2,086
- References
- 232
- Citations by year
- 2026: 771 · 2025: 903 · 2024: 408 · 2023: 1
- FWCI
- 74.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (K23DK121942)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- diabetes diagnosis, diabetes classification, diabetes mellitus, clinical guidelines, American Diabetes Association standards of care, quality of care
- MeSH terms
- Diabetes Mellitus, Endocrinology, Humans, Reference Standards, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.